Growth Factor News and Research

RSS

CSHL researchers describe new pathway that controls fear memories in the mouse brain

Some people have no fear, like that 17-year-old kid who drives like a maniac. But for the nearly 40 million adults who suffer from anxiety disorders, an overabundance of fear rules their lives. Debilitating anxiety prevents them from participating in life's most mundane moments, from driving a car to riding in an elevator.

20 Jan 2015

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

New article discusses role of cytokines in breast cancer development, progression

Emerging data on the role of inflammation and the immune system in the development, growth, and spread of breast tumors have focused increased attention on the role cytokines such as interleukin and transforming growth factor-β play in breast cancer initiation, protection, and metastasis.

14 Jan 2015

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer.

12 Jan 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer.

From QIAGEN Manchester Limited 12 Jan 2015

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

8 Jan 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

Study: Placental cells may possibly treat damaged nerves

New findings suggest that placental cells may potentially treat damaged nerves possibly leading the way to new treatment for stroke patients.

5 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center.

23 Dec 2014

Chromosome X microduplications implicated in infancy-onset gigantism

Researchers report that heritable microduplications on chromosome Xq26.3 may underlie a “striking” form of gigantism with onset in late infancy, and reveal a candidate culprit gene.

22 Dec 2014

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests.

19 Dec 2014

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Ortho-Clinical Diagnostics announces availability of NEPHROCHECK Test System for AKI patients

Ortho-Clinical Diagnostics, Inc. today announced the nationwide availability to hospitals of the NEPHROCHECK Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment.

From Ortho-Clinical Diagnostics, Inc. 16 Dec 2014

Joslin study could lead to improved anti-aging drugs

In a study published today by Nature, researchers at Joslin Diabetes Center used a microscopic worm (C. elegans) to identify a new path that could lead to drugs to slow aging and the chronic diseases that often accompany it--and might even lead to better cosmetics.

16 Dec 2014

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

16 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute-supported clinical trials that demonstrated that trastuzumab significantly improves the long-term survival of HER-2 positive breast cancer patients.

16 Dec 2014

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report.

15 Dec 2014

Growth Factor News and Research

CSHL researchers describe new pathway that controls fear memories in the mouse brain

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

New article discusses role of cytokines in breast cancer development, progression

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Using HIV drugs to treat AMD: an interview with Dr Mark Young

Study: Placental cells may possibly treat damaged nerves

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

Chromosome X microduplications implicated in infancy-onset gigantism

Long-term axitinib in RCC effective with ‘controllable’ toxicities

RCC renal function independent of axitinib-induced proteinuria

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Ortho-Clinical Diagnostics announces availability of NEPHROCHECK Test System for AKI patients

Joslin study could lead to improved anti-aging drugs

UT Southwestern researchers identify cell signaling mechanism that plays vital role in brain cancer

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Trastuzumab drug improves long-term survival of patients with HER-2 positive breast cancer

Postoperative recurrent disease affects NSCLC survival after gefitinib

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News